



CLAIMS

1. A modified oligonucleotide according to the following formula:



(SEQ ID NO: 33) or a salt thereof.

2. A modified oligonucleotide according to the following formula:



(SEQ ID NO: 33).

3. The modified oligonucleotide of claim 1, which is a sodium salt of the formula.
4. A pharmaceutical composition comprising the modified oligonucleotide of claim 1 and a pharmaceutically acceptable carrier or diluent.
5. The pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS).
6. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and phosphate-buffered saline (PBS).

7. A pharmaceutical composition comprising the modified oligonucleotide of claim 3 and a pharmaceutically acceptable carrier or diluent.
8. The pharmaceutical composition of claim 7, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS).
9. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and phosphate-buffered saline (PBS).
10. A pharmaceutical composition comprising the modified oligonucleotide of claim 2 and a pharmaceutically acceptable carrier or diluent.
11. The pharmaceutical composition of claim 10, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS).
12. The pharmaceutical composition of claim 10, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and phosphate-buffered saline (PBS).
13. A compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is a gapmer consisting of a 5' wing segment, a central gap segment, and a 3' wing segment, wherein:
 - the 5' wing segment consists of four 2'-O-methoxyethyl nucleosides,
 - the central gap segment consists of eight β -D-deoxyribonucleosides, and
 - the 3' wing segment consists of six 2'-O-methoxyethyl nucleosides;wherein the modified oligonucleotide has the nucleobase sequence 5'-GCCCCTAGCGCGCGACTC-3' (SEQ ID NO: 33), wherein each cytosine is a 5-methylcytosine; and wherein the internucleoside linkages of the modified oligonucleotide are, from 5' to 3', soossssssssoooss, wherein each s is a phosphorothioate linkage and each o is a phosphodiester linkage.
14. The compound of claim 13, comprising the modified oligonucleotide covalently linked to a conjugate group.
15. A pharmaceutical composition comprising the compound of claim 13 and a pharmaceutically acceptable diluent or carrier.

16. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS).
17. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition consists essentially of the compound and phosphate-buffered saline (PBS).
18. A pharmaceutical composition comprising the compound of claim 14 and a pharmaceutically acceptable diluent or carrier.
19. The pharmaceutical composition of claim 18, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS).
20. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition consists essentially of the compound and phosphate-buffered saline (PBS).